Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Canadian Federal Court has ruled that Pfizer's patent covering a crystalline form of atorvastatin, the active ingredient in Lipitor, would be infringed by Ranbaxy's process for making its proposed generic atorvastatin product.
Subscribe to our email newsletter
The court has ordered Ranbaxy to delay launching its product until expiration of the patent in July 2016. Ranbaxy may seek to appeal this decision.
However, the court denied Pfizer’s application for a prohibition order in connection with a second patent covering a process for making amorphous atorvastatin, which also expires in July 2016.